GovChime
Notice ID: 4292c8a189754fc8b56056415de493ccAward NoticeAwardedArchived

NOTICE OF AWARD COMPOUND PHARMACEUTICALS

Awarded on March 3, 2026. The description is published on SAM.gov: Full description on SAM.gov.

Awarded tounder W81K0026PA026 (source: SAM.gov award notice)• $582.4K

Overview

Posted
March 3, 2026
Notice type
Award Notice
Set-aside
Total Small Business Set-Aside (FAR 19.5)
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of WarDepartment of the Army

Notice details

Office
US ARMY MEDICAL COMMAND.US ARMY HEALTH CONTRACTING ACTIVITY.W40M MRC0 WEST
Place of performance
Fort Hood, Texas, 76544
Last updated
Nov 2, 2026
First published
Last updated on SAM.gov
Award date
Mar 3, 2026
Award amount (SAM.gov award notice)
$582.4K

Identifiers

Solicitation number
W81K0026PA026
Notice ID
4292c8a189754fc8b56056415de493cc
Award number (PIID)
W81K0026PA026

Description

No description in the SAM.gov data feed for this notice.

Full description on SAM.gov

Award Overview

Award Number

W81K0026PA026

Award Amount (SAM.gov award notice)

$582.4K

Award Date

Mar 3, 2026

Awardee

Awardee UEI

LDNAY53JNV24

Awardee CAGE Code

895Y5

Awardee Address

Pittsboro, NC 27312, UNITED STATES

Original Solicitation

Notice ID: 4292c8a189754fc8b56056415de493cc

Posted Date: Mar 3, 2026

Original Response Deadline: Not specified

More From This Vendor

Top 5 most recent

5
  • W81K0026PA179
    AMERICAN NATIONAL SERVICES LLC
    Department of DefenseNAICS 325412
    —Signed Jul 28, 2026
  • HT940625FE032
    AMERICAN NATIONAL SERVICES LLC
    Department of DefenseNAICS 325412
    $401.5KSigned Dec 16, 2025
  • W81K0024P0187
    AMERICAN NATIONAL SERVICES LLC
    Department of DefenseNAICS 325412
    $194.1KSigned Dec 10, 2025
  • HT940625FE032
    AMERICAN NATIONAL SERVICES LLC
    Department of DefenseNAICS 325412
    $401.5KSigned Nov 14, 2025
  • HT940625FE032
    AMERICAN NATIONAL SERVICES LLC
    Department of DefenseNAICS 325412
    $401.5KSigned Sep 25, 2025

Contacts

Contracting Officer

Primary Contact

Secondary Contact

Documents

No documents available.

Lifecycle

  1. 3
    Version 3Award NoticeArchivedCurrent

    NOTICE OF AWARD COMPOUND PHARMACEUTICALS

    Notice 4292c8a189754fc8b56056415de493cc on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Radiopharmaceutical microspheres for William Beaumont Army Medical Center (WBAMC), Fort Bliss, TX, to support ongoing selective internal radiation therapy (SIRT) for patients presenting with unresectable metastic liver tumores secondary to colorectal cancer.
-AwardedOpen
Sources Sought Notice The Department of Veterans Affairs, Network Contracting Office (NCO) 17, is seeking sources for the following procurement: NETSPOT® Gallium Ga 68 Dotatate Injection Item (radiopharmaceutical) will be delivered to the VA North Texas Health Care System, 4500 S. Lancaster Rd., Dallas, TX 75216-7167. NCO 17 is seeking sources from firms that are capable of providing this item. Firms that can provide this item are encouraged to respond to the sources sought notice by contacting the point of contact. Capable firms must respond to the POC before the closing date and time of the notice to be considered. Capable firms must identify with their company name and are encouraged to provide a capabilities statement (if readily available) with their response. This notice is NOT a formal request for quote or proposals. No formal solicitation document exists at this time. The information in this notice is for information and planning purposes only and is not to be construed as a commitment by the government. No contract will be awarded from this notice.
-Special Notice10/30/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics – NA i. Mimrylo - Hematological Agents – NA j. Nuzolvence - Antibiotics – NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
-Solicitation10/26/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Awiqli Flextouch - Insulin - Basal b. Cavhanza - Leukemia and Lymphoma Agents - BCR-ABL Tyrosine Kinase Inhibitors c. Lipfendra - Antilipidemics-1 - PCSK-9 d. Trutakna - Nephrology Agents Miscellaneous - NA The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9402. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
-Solicitation08/27/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 drug classes/subclasses will be reviewed: a. Atopy - Topical Agents Anzupgo Eucrisa Opzelura Vtama Zoryve b. Lung Cancer - METEX14 Tabrecta Tepmetko The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9401. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference.
-Solicitation10/01/2026

Additional Details

Solicitation Number

W81K0026PA026

Archive Date

Mar 18, 2026

Office Address

JBSA FT SAM HOUSTON, TX, 78234-4504